Aktienanalyse zu Insulet Corp (PODD)PODDInsulet Corp

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Insulet Corp (PODD) is a good buy right now, with a current price of $135.28 and a forward P/E ratio of 54.95, indicating potential for growth despite recent declines. The stock has seen a 2.73% increase over the last 5 days, and insider buying has surged by 409.88%, reflecting confidence in the company's future. However, the main risk is the significant year-to-date decline of 52.18%, which may affect investor sentiment.

17 analysts cover PODD: 10 rate it Buy, 7 Hold and 0 Sell. The average price target is 375.83.